To support its growth plans, HBC intends to convert its facility in Berkak into a state-of-the-art enzymatic hydrolysis plant that will triple the company’s current production.

“This partnership with HBC is testament to their unique footprint and differentiated science. Their investments in clinical studies demonstrate proven benefits in key categories of metabolic health, immune health, gut health and mobility, setting them apart. This partnership is well aligned with our willingness to accelerate in health in the context of our “One Care“ journey but also with the recent creation of the Global Marine Platform to explore the vast potential that the oceans could offer us,” said Jean-Yves Parisot, CEO of Symrise.

HBC has developed a proprietary technology to upcycle fresh salmon offcuts not used in the production of fillets into bioactive ingredients with demonstrated health benefits.

Jon Olav Odegard, CEO of HBC, commented: “The human health and premium pet markets continue to grow very strongly, and this partnership will allow us to sustain our growth trajectory and position us as the leading player in the science-led marine nutrition segment dedicated to human health.”